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Wake Forest University School of Medicine Winston-Salem, North Carolina 27157 During the formation of cleavage furrow of mitosis, phosphatidylethanolamine (PE) flips from inner leaflet of the plasma membrane to the outer leaflet specifically in the furrow region near the contractile ring. Iinmediately after the contractile ring separates the two daughter cells, PE returns from outer leaflet to imier leaflet This transient movement of PE during cytokinesis is essential because blockage of this PE n^^^^^^^j.''^^.^^^ "^^^^^^^^ failure of mitosis and leads to cell death. Cimiamycin produced by StreptoverticiUium gnseoverticiatum targets specifically to PE on cell surface at the cleavage furrow of mitotic cells but not the non-dividing cells. This proposal is to test if cimiamycin is a better anti-tumor drug for treatment of breast cancers because of several advantages: 1) Cimiamycin only targets proliferating cells but has no effect on non-proliferatog eel s.
2) The anti-proliferation activity doesn't require cimiamycin to enter the cells. 3) Cimiamycm doesn't have to suffer the effect of multi-drug resistance mechanism or cellular metabolism. Because cinnamycm is no longer available commercially, we had to devise production procedures and to purify this compound m our own lab. Thus, completion of this proposal would require longer time than that was onginally proposed. 
SUBJECT TERMS
Final Report
Introduction
During the formation of cleavage furrow of mitosis, phosphatidylethanolamine (PE) flips from iimer leaflet of the plasma membrane to the outer leaflet specifically in the furrow region near the contractile ring. Immediately after the contractile ring separates the two daughter cells, PE returns from outer leaflet to inner leaflet. This transient movement of PE during cytokinesis is essential because blockage of this PE movement results in a failure of mitosis and leads to cell death. Cinnamycin produced by Streptoverticillium griseoverticillatum targets specifically to PE on cell surface at the cleavage furrow of mitotic cells but not the non-dividing cells. This proposal is to test if cinnamycin is a better anti-tumor drug for treatment of mammary cancer models in mice.
Body
Because cinnamycin is no longer available commercially, we had to devise production procedures and to purify this compound in our own lab. Thus, completion of this proposal would require longer time than that was originally proposed, hi the initial funding period, we have performed extensive literature search for commercial source of cinnamycin suppliers. However, none of the previous suppliers continues to sell this compound. We proceeded to contact several academic investigators who have published using this compound. All these investigators have stopped to use this compound and no longer have it in their possession. Thus we have decided to produce and purify this compound in our own lab.
Key Research Accomplishments
During the residual funding period since last report, we have attempted to produce and isolate cinnamycin from cell culture of bacteriimi Streptoverticillium griseoverticillatum.
Reportable Outcomes
None.
Conclusions
Cinnamycin is an old compound that is no longer produced by any commercial source or by academic entity. Thus our goal to test its anti-breast cancer effect could not be performed as we originally planned. The emphasis then changed to production of cinnamycin in our own lab. Although several attempts were made to purify the peptide, we were not able to isolate enough peptide to perfomi any test in cell culture experiment and animal experiments in the proposed budget and time frame. However, we will continue to isolate cinnamycin in our lab as well as to search collaboration partners who had experience in isolation of the peptide even after this funding is over. Once enough cinnamycin is obtained, we will seek other funding resources to perfonn tests in animals.
